WO2009009935A1 - Virus recombinant déficient en réplication, composition pharmaceutique le comprenant et ses utilisations - Google Patents

Virus recombinant déficient en réplication, composition pharmaceutique le comprenant et ses utilisations Download PDF

Info

Publication number
WO2009009935A1
WO2009009935A1 PCT/CN2007/003441 CN2007003441W WO2009009935A1 WO 2009009935 A1 WO2009009935 A1 WO 2009009935A1 CN 2007003441 W CN2007003441 W CN 2007003441W WO 2009009935 A1 WO2009009935 A1 WO 2009009935A1
Authority
WO
WIPO (PCT)
Prior art keywords
replication
lfa3
human
virus
cells
Prior art date
Application number
PCT/CN2007/003441
Other languages
English (en)
Chinese (zh)
Inventor
Weiyue Han
Kai He
Yong Yang
Liming Yang
Renhuai Zhang
Shaodong Zhong
Yalei Wen
Hongguang Li
Bo He
Qi Tang
Original Assignee
Dongguan Taili Biotech Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dongguan Taili Biotech Co., Ltd. filed Critical Dongguan Taili Biotech Co., Ltd.
Publication of WO2009009935A1 publication Critical patent/WO2009009935A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention porte sur un virus recombinant déficient en réplication, comprenant un gène de fusion humain LFA3-Fc sous le contrôle d'un promoteur. Le gène de fusion humain LFA3-Fc est fusionné par domaine extracellulaire soluble de LFA3 humain et d'un fragment Fc d'une IgG humaine. L'invention porte également sur une composition pharmaceutique contre le psoriasis, comprenant le virus déficient en réplication et un pansement pharmaceutique acceptable. L'injection de la composition pharmaceutique contre le psoriasis produite par le procédé selon la présente invention peut amener la protéine cible à être exprimée in vivo pendant un long moment, les temps d'administration peuvent par conséquent être réduits.
PCT/CN2007/003441 2007-07-16 2007-12-04 Virus recombinant déficient en réplication, composition pharmaceutique le comprenant et ses utilisations WO2009009935A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200710130548.8 2007-07-16
CNA2007101305488A CN101113459A (zh) 2007-07-16 2007-07-16 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用

Publications (1)

Publication Number Publication Date
WO2009009935A1 true WO2009009935A1 (fr) 2009-01-22

Family

ID=39021988

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/003441 WO2009009935A1 (fr) 2007-07-16 2007-12-04 Virus recombinant déficient en réplication, composition pharmaceutique le comprenant et ses utilisations

Country Status (2)

Country Link
CN (1) CN101113459A (fr)
WO (1) WO2009009935A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101113459A (zh) * 2007-07-16 2008-01-30 东莞太力生物工程有限公司 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用
CN109280644B (zh) * 2018-09-04 2023-02-17 四川安可瑞新材料技术有限公司 抗人IgG单克隆抗体、其杂交瘤细胞株及应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
CN1315866A (zh) * 1998-08-31 2001-10-03 拜奥根有限公司 使用cd2－结合剂调节记忆效应t－细胞的方法和组合物
CN1373672A (zh) * 1999-07-12 2002-10-09 杰南技术公司 应用结合cd20的拮抗剂阻断对外来抗原的免疫应答
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
CN1527723A (zh) * 2001-02-01 2004-09-08 ¸ 用cd2-结合剂治疗或预防皮肤病症的方法
CN1953766A (zh) * 2004-02-06 2007-04-25 安斯泰来美国有限公司 治疗皮肤病的方法
CN101113459A (zh) * 2007-07-16 2008-01-30 东莞太力生物工程有限公司 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162432A (en) * 1991-10-07 2000-12-19 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
CN1315866A (zh) * 1998-08-31 2001-10-03 拜奥根有限公司 使用cd2－结合剂调节记忆效应t－细胞的方法和组合物
CN1373672A (zh) * 1999-07-12 2002-10-09 杰南技术公司 应用结合cd20的拮抗剂阻断对外来抗原的免疫应答
CN1527723A (zh) * 2001-02-01 2004-09-08 ¸ 用cd2-结合剂治疗或预防皮肤病症的方法
CN1953766A (zh) * 2004-02-06 2007-04-25 安斯泰来美国有限公司 治疗皮肤病的方法
CN101113459A (zh) * 2007-07-16 2008-01-30 东莞太力生物工程有限公司 一种重组复制缺陷型病毒、含有该病毒的药物组合物及其应用

Also Published As

Publication number Publication date
CN101113459A (zh) 2008-01-30

Similar Documents

Publication Publication Date Title
JP6325459B2 (ja) 腫瘍関連異種抗原を発現するアデノウイルス
US20210154329A1 (en) ANTI-TUMOR COMPOSITION COMPRISING GM-CSF GENE, Flt3L-TRAIL FUSION GENE, shRNA INHIBITING TGF-ß EXPRESSION, AND shRNA INHIBITING HSP EXPRESSION
JP7438552B2 (ja) 注射用医薬品、注射用調製物、および注射用医薬品の製造における使用
JP2020521471A (ja) 導入遺伝子を保持する組換えアデノウイルス
KR20190098215A (ko) 무장된 복제-가능 종양 분해 아데노바이러스
JP7420751B2 (ja) Ｉ型インターフェロン及びｃｄ４０－配位子を用いる腫瘍溶解性ウイルス又は抗原提示細胞媒介性癌治療
JP2020516293A (ja) 複数トランスジーン組み換えアデノウイルス
BR112020019303A2 (pt) Adenovírus oncolíticos modificados
CN111133102A (zh) 生产重组病毒的方法
WO2015149708A1 (fr) Nouvelle protéine de fusion bifonctionnelle recombinante, son procédé de préparation et son utilisation
WO2021239020A1 (fr) Procédé d'immunothérapie pour combiner un récepteur d'antigène chimère et un interféron de type i et application de celui-ci
CN116348496A (zh) Bcma嵌合抗原受体
WO2009009935A1 (fr) Virus recombinant déficient en réplication, composition pharmaceutique le comprenant et ses utilisations
EP2128261B1 (fr) Adénovirus recombinant comprenant un gène khp53 recombinant et son procédé de préparation et ses utilisations
KR20240022572A (ko) Tnfsf-l 융합 단백질 및 그의 용도
CN114657150A (zh) 用于改善免疫疗法的重组溶瘤腺病毒及其应用
CN112501176B (zh) 一种多核苷酸及其应用
WO2023093888A1 (fr) Préparation et utilisation de cellules immunitaires d'un récepteur antigénique chimérique construit sur la base de efna1
WO2023241522A1 (fr) Récepteur de lymphocytes t ciblant un polypeptide mutant kras g12v, et son utilisation
EP3242939A2 (fr) Molécules d'adn produisant des virus à arn à brin négatif de réplication et de non-réplication de conception personnalisée et leurs utilisations
CN117683147A (zh) 嵌合抗原受体、慢病毒、修饰t细胞及其应用
JP3084448B2 (ja) 哺乳動物細胞への腫瘍壊死因子及び抗Ｆａｓ抗体に対する耐性の付与方法
CN115477705A (zh) 一种基于颗粒酶b构建的嵌合抗原受体免疫细胞制备及其应用
JP2000143548A (ja) レトロウイルスの感染性を増大させるための方法および組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07845802

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07845802

Country of ref document: EP

Kind code of ref document: A1

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 16-06-2010)

122 Ep: pct application non-entry in european phase

Ref document number: 07845802

Country of ref document: EP

Kind code of ref document: A1